Hepatitis A screening: Difference between revisions
Jump to navigation
Jump to search
Tarek Nafee (talk | contribs) No edit summary |
Tarek Nafee (talk | contribs) |
||
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
There is no recommended screening guideline for Hepatitis A infection. However, | There is no recommended screening guideline for Hepatitis A infection in the general population. However, screening is often performed in young adult migrants. The detection of [[hepatitis A virus]] (HAV) [[antibodies]] in the blood is used to screen for [[hepatitis A]]. Anti-[[HAV]] [[IgG]] remains elevated after acute disease.<ref name=CDC>{{cite web | title = Hepatitis A Screening | url = http://www.ncbi.nlm.nih.gov/books/NBK92029/ }}</ref> | ||
==Screening== | ==Screening== |
Revision as of 13:12, 2 November 2016
Hepatitis A |
Diagnosis |
Treatment |
Case Studies |
Hepatitis A screening On the Web |
American Roentgen Ray Society Images of Hepatitis A screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
There is no recommended screening guideline for Hepatitis A infection in the general population. However, screening is often performed in young adult migrants. The detection of hepatitis A virus (HAV) antibodies in the blood is used to screen for hepatitis A. Anti-HAV IgG remains elevated after acute disease.[1]
Screening
A positive anti-HAV IgG result demonstrates that the person is immune to hepatitis A due to: [1]
- Previous HAV infection, or
- Hepatitis A vaccination
A negative test demonstrates that the person:[1]
- Has never been infected with HAV
- Has never been vaccinated against HAV
- Is vulnerable to the HAV infection